Selective Metabotropic Glutamate Receptor 5 (mGlu5) Antagonism Reduces L-DOPA-Induced Dyskinesia in MPTP-Lesioned Primates at the Expense of Anti-Parkinsonian Benefit

被引：0
|
作者：
Johnston, Tom H.
Fox, Susan H.
Piggott, Matthew J.
Brotchie, Jonathan M.
机构：
来源：
NEUROLOGY | 2010年 / 74卷 / 09期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：A84 / A84
页数：1
相关论文
共 50 条
  • [1] Safinamide causes dose-dependent reduction of L-DOPA-induced dyskinesia while prolonging anti-parkinsonian efficacy in MPTP-lesioned primates
    Gregoire, L.
    Roach, A.
    Di Paolo, T.
    EUROPEAN JOURNAL OF NEUROLOGY, 2010, 17 : 100 - 100
  • [2] The highly-selective 5-HT1A agonist F15599 reduces L-DOPA-induced dyskinesia without compromising anti-parkinsonian benefits in the MPTP-lesioned macaque
    Huot, Philippe
    Johnston, Tom H.
    Fox, Susan H.
    Newman-Tancredi, Adrian
    Brotchie, Jonathan M.
    NEUROPHARMACOLOGY, 2015, 97 : 306 - 311
  • [3] Satinamide reduces levodopa-induced dyskinesia in MPTP-lesioned primates while prolonging anti-parkinsonian efficacy
    Gregoire, L.
    Roach, A.
    Di Paolo, T.
    MOVEMENT DISORDERS, 2010, 25 (07) : S411 - S412
  • [4] FP0011 extends the duration of the anti-parkinsonian actions of L-DOPA and reduces L-DOPA-induced dyskinesia in the MPTP-lesioned macaque model of Parkinson's disease
    Brotchie, J. M.
    Johnston, T. H.
    Fox, S. H.
    Zerr, P.
    Tiberghien, F.
    Bossi, L.
    MOVEMENT DISORDERS, 2007, 22 : S95 - S95
  • [5] Selective metabotropic glutamate receptor 2 positive allosteric modulation alleviates L-DOPA-induced psychosis-like behaviours and dyskinesia in the MPTP-lesioned marmoset
    Sid-Otmane, Lamia
    Hamadijda, Adjia
    Nuara, Stephen G.
    Bedard, Dominique
    Gaudette, Fleur
    Gourdon, Jim C.
    Michaud, Veronique
    Beaudry, Francis
    Panisset, Michel
    Huot, Philippe
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2020, 873
  • [6] Seletracetam (UCB 44212) reduces L-dopa-induced dyskinesia in the MPTP-lesioned marmoset model of Parkinson's disease
    Michel, A
    Ravenscroft, P
    Hill, MP
    Bezard, E
    Crossman, AR
    Klitgaard, H
    MOVEMENT DISORDERS, 2005, 20 : S102 - S102
  • [7] The α2-adrenergic receptor antagonist idazoxan reduces dyskinesia and enhances anti-parkinsonian actions of L-dopa in the MPTP-lesioned primate model of parkinson's disease
    Henry, B
    Fox, SH
    Peggs, D
    Crossman, AR
    Brotchie, JM
    MOVEMENT DISORDERS, 1999, 14 (05) : 744 - 753
  • [8] MPEP, an mGlu5 receptor antagonist, reduces the development of L-DOPA-induced motor complications in de novo parkinsonian monkeys: Biochemical correlates
    Morin, Nicolas
    Gregoire, Laurent
    Morissette, Marc
    Desrayaud, Sandrine
    Gomez-Mancilla, Baltazar
    Gasparini, Fabrizio
    Di Paolo, Therese
    NEUROPHARMACOLOGY, 2013, 66 : 355 - 364
  • [9] Anti-parkinsonian effects of delta opioid receptor stimulation are accompanied by dystonia in MPTP-lesioned non-human primates previously treated with L-DOPA
    Johnston, T
    Fox, SH
    Gomez-Ramirez, J
    Lee, J
    Brotchie, JM
    MOVEMENT DISORDERS, 2004, 19 : S398 - S399
  • [10] ADX48621, a novel mGlu5 negative allosteric modulator alleviates L-DOPA-induced chorea and dystonia in the MPTP-lesioned macaque model of Parkinson's disease
    Hill, M. P.
    Girard, F.
    Keywood, C.
    Poli, S. -M.
    Crossman, A. R.
    Ravenscroft, P.
    Li, Q.
    Bezard, E.
    Mutel, V.
    MOVEMENT DISORDERS, 2010, 25 (07) : S281 - S282
12345